They've already run trials going through the dose levels that were problematic for CX717. The FDA was not going to take a risk of looking lax on a drug that had a safety signal, artifact or not. Without a caution flag, it won't be an issue for CX-1739.
RD upfront: $3-4 million. They need $3-4 million plus 9 months operating expenses to do an ADHD trial, so it won't be enough to get it completed--since they then have to be able to analyze the data and, if positive, partner it.
NeuroInvestment
News 
Market Data 
Discover 
AI
